A standing ovation for RevMed, and caution for Akeso

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.

Matthew Herper covers medical innovation — both its promise and its perils.

Katherine MacPhail is a reporter and editorial events programmer for STAT.

Angus reports on the basic research, clinical science, and drug development that may transform survival and quality of life for patients, as well as developments affecting the cancer community. You can reach Angus on Signal at angus.08.

You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology annual meeting. Sign up for email editions here.

Oncologists are capable of some raucous applause, but they don’t bestow it upon just anyone. Today saw one of those coveted standing ovations, and the hoots and cheers were not held for the end.

The plenary may have passed, but ASCO isn’t over yet— we’ll be back tomorrow with our final newsletter installment, and you can catch our virtual recap on Wednesday.

STAT+ Exclusive Story

Medicaid work requirement rules published by Trump’s CMS